June 9, 2020 / 12:51 PM / a month ago

BRIEF-Dynavax Completes Enrollment Of Trial Evaluating Heplisav-B

June 9 (Reuters) - Dynavax Technologies Corp:

* DYNAVAX COMPLETES ENROLLMENT OF CLINICAL TRIAL EVALUATING HEPLISAV-B IN PATIENTS UNDERGOING HEMODIALYSIS

* DYNAVAX TECHNOLOGIES CORP - TRIAL ENROLLED 119 PATIENTS WITH END-STAGE RENAL DISEASE UNDERGOING HEMODIALYSIS

* DYNAVAX TECHNOLOGIES CORP - ANTICIPATES FINAL IMMUNOGENICITY STUDY DATA FROM CLINICAL TRIAL EVALUATING HEPLISAV-B IN Q4 OF 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below